Saltar al contenido
PivotalWire 10 ago 2026

Empresas›RGNX

RGNX · REGENXBIO Inc.

productos biologicos · CIK 0001590877

Documentos
15
recogidos hasta hoy
Ultimo
6 ago 2026
Hecho relevante

Todavia no se publican los trimestres de caja ni la dilucion de esta empresa: hacen falta datos de sus informes que solo se recogen de las que se siguen de cerca. Lo que ves abajo son sus documentos tal y como los presento ante la SEC.

Documentos presentados ante la SEC

2026

  1. 8-KHecho relevanteEDGAR
  2. 10-QInforme trimestralEDGAR
    Parada clinica impuesta por la FDA…ovember 9, 2025 to February 8, 2026. In January 2026, we announced that the FDA placed the RGX-121 program on partial clinical hold in relation to a serious adverse event in a patient treated in the Phase I/II t…
  3. 4Operacion de un directivo o accionista significativoEDGAR
  4. 4Operacion de un directivo o accionista significativoEDGAR
  5. 8-KHecho relevanteEDGAR
  6. FWPFWPEDGAR
  7. 424B5Nueva emision de acciones con precioEDGAR
    Duda sustancial sobre la continuidad de la empresa…xt 12 months from the date of this prospectus supplement. As a result, there is substantial doubt about our ability to continue as a going concern. Drug development is a lengthy, expensive, and uncertain process, and our produ…
    Parada clinica impuesta por la FDA…ovember 9, 2025 to February 8, 2026. In January 2026, we announced that the FDA placed the RGX-121 program on partial clinical hold in relation to a serious adverse event in a patient treated in the Phase I/II t…
  8. 424B5Nueva emision de acciones con precioEDGAR
    Duda sustancial sobre la continuidad de la empresa…xt 12 months from the date of this prospectus supplement. As a result, there is substantial doubt about our ability to continue as a going concern. Drug development is a lengthy, expensive, and uncertain process, and our produ…
    Parada clinica impuesta por la FDA…ovember 9, 2025 to February 8, 2026. In January 2026, we announced that the FDA placed the RGX-121 program on partial clinical hold in relation to a serious adverse event in a patient treated in the Phase I/II t…
  9. SC TO-I/ASC TO-I/AEDGAR
  10. 4Operacion de un directivo o accionista significativoEDGAR
  11. 4Operacion de un directivo o accionista significativoEDGAR
  12. SC TO-I/ASC TO-I/AEDGAR
  13. 144Aviso de venta de acciones restringidasEDGAR
  14. 4Operacion de un directivo o accionista significativoEDGAR
  15. 8-KHecho relevanteEDGAR